State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet?

For instance, in the Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease (SIROCCO) trial comparing the SMART-sirolimus-eluting stent versus BMS at 6 months, the sirolimus stent group showed a trend toward lower in-stent mean percent diameter stenosis than BMS (22.6% vs 30.9%; P = .294). 82 However, initial enthusiasm was dampened when results at 18 months indicated no significant differences in outcomes. 83 , 84 Similarly, the single-arm STRIDES study evaluating the Dynalink-everolimus-elutin

also in 53,322 other papers